Loading organizations...
Braidwell is a Stamford, Connecticut-based hedge fund manager that provides flexible debt and equity capital to public and private companies operating across all stages of development within the human health and life sciences sectors. The firm utilizes a long/short equity investment strategy to generate returns across various parts of the capital structure. To evaluate these opportunities, the organization leverages internal expertise spanning medical science, biostatistics, commercial analysis, financial structuring, data science, and artificial intelligence. Operating with a specialized team of approximately 38 employees, the firm currently manages 10 distinct hedge funds and generates under $5 million in annual revenue. As part of its broader investment portfolio, the firm has provided senior secured debt financing to notable biotechnology enterprises such as Caris Life Sciences. Braidwell was founded in 2021 by managing members Alex Karnal and Brian Kreiter.
Key people at Braidwell.
Braidwell has 6 tracked investments across 6 companies. The latest tracked deal is $80.0M Seed in Proxima in January 2026.
Key people at Braidwell.
Braidwell is a US-based investment firm founded in 2021, specializing in life sciences and human health transformation. It provides flexible capital and thoughtful partnership to companies across all development stages and capital structures, including public, private, and structured markets, through a long/short equity strategy aimed at long-term returns[1][2][3]. The firm's mission centers on serving organizations advancing human health, leveraging a close-knit team of scientific, medical, financial, technological, and operational leaders to foster deep understanding of life science assets[2][3]. Key sectors include biotechnology and life sciences, with a notable impact on the startup ecosystem via non-dilutive financing like term loans and investments in firms such as Caris Life Sciences and Krystal Biotech, managing approximately $5.2 billion in assets under management (AUM)[3][4][5].
Braidwell was established in 2021 as a hedge fund manager based in Stamford, Connecticut, quickly evolving into a multifaceted investor focused on life sciences[1][4]. Key partners form a compact team of experts in science, medicine, finance, technology, and operations, though specific founder names are not detailed in available records[2]. The firm's focus has rapidly sharpened on human health innovation, expanding from long/short equity to flexible deployments across capital markets, evidenced by early deals like a $150 million non-dilutive term loan and holdings in clinical-stage biotechs[3][4].
Braidwell rides the wave of life sciences innovation, particularly in precision medicine, oncology, and biotech amid surging demand for transformative health technologies. Timing aligns with post-pandemic biotech resurgence and aging populations driving R&D needs, bolstered by market forces like favorable interest rates for structured financing and regulatory tailwinds for novel therapies[2][4]. The firm influences the ecosystem by providing patient capital to high-risk innovators—e.g., clinical-stage players like Xenon Pharmaceuticals—enabling scale without dilution and bridging public-private gaps in a sector where traditional VC often falls short[3][4].
Braidwell's trajectory points to expanded AUM and deeper life sciences penetration, with trends like AI-driven drug discovery and gene therapies shaping its portfolio—evident in recent activity adding stakes in Caris Life Sciences and Nuvalent[4]. Influence may grow via more structured deals in a volatile market, potentially evolving into a go-to partner for health tech scaling globally. This positions Braidwell to sustain long-term returns while fueling the fight against disease, echoing its core mission of flexible capital for human health pioneers[2].
